Trial reportThorax2015
Targeted lung denervation for moderate to severe COPD: a pilot study.
Trial report in Thorax, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01483534 (Evaluation of the Innovative Pulmonary Solutions), which is not on this map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation (TLD) Therapy in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) - A Safety Study
Who cites it
40 citing papers in PubMed, 96 citations in OpenAlex.
- Randomized Sham-controlled Trial of Targeted Lung Denervation in Patients with Chronic Obstructive Pulmonary Disease (AIRFLOW-3).American journal of respiratory and critical care medicine · 2025Trial
- Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2.International journal of chronic obstructive pulmonary disease · 2020Trial
- Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial.American journal of respiratory and critical care medicine · 2019Trial
- Safety and Dose Study of Targeted Lung Denervation in Moderate/Severe COPD Patients.Respiration; international review of thoracic diseasesTrial
- A novel targeted lung denervation multi-polar radiofrequency ablation system for moderate to severe COPD patients: a translational study.Respiratory research · 2026Article
- Targeted Lung Denervation in Chronic Obstructive Pulmonary Disease: Threading the Needle of Safe Interventions to Help the Sickest.American journal of respiratory and critical care medicine · 2025Article
- Interventional pulmonology for chronic inflammatory airway diseases.Chinese medical journal pulmonary and critical care medicine · 2024Review
- ERJ Advances: interventional bronchoscopy.The European respiratory journal · 2024Article
- Effects of human umbilical cord blood mononuclear cells on ovalbumin-induced asthma in mice.Journal of thoracic disease · 2023Article
- Outcomes of bronchoscopic lung volume reduction coil treatment in patients with severe emphysema.Turk gogus kalp damar cerrahisi dergisi · 2023Article
- Review
- Bronchoscopic Management of COPD and Advances in Therapy.Life (Basel, Switzerland) · 2023Review
- Which Endoscopic Procedure to Use and in What Patient? Valves, Coils, Foam, and Heat in COPD and Asthma.Pulmonary therapy · 2023Review
- Modern Bronchoscopic Treatment Options for Patients with Chronic Bronchitis.Journal of clinical medicine · 2023Article
- Targeted lung denervation modulates the mucosal epithelial transcriptome in COPD.ERJ open research · 2022Article
- Current status of interventional therapy for pulmonary emphysema with bronchoscopy.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Review
- Bronchoscopic Targeted Lung Denervation in Patients with Severe Asthma: Preliminary Findings.Respiration; international review of thoracic diseases · 2022Article
- Polarization-sensitive optical coherence tomography in end-stage lung diseases: an ex vivo pilot study.Biomedical optics express · 2021Article
- ERS International Congress 2020: highlights from the Clinical Techniques, Imaging and Endoscopy assembly.ERJ open research · 2021Review
- New bronchoscopic treatment modalities for patients with chronic bronchitis.European respiratory review : an official journal of the European Respiratory Society · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParasympathetic pulmonary nerves release acetylcholine that induces smooth muscle constriction. Disruption of parasympathetic pulmonary nerves improves lung function and COPD symptoms.
aimsTo evaluate 'targeted lung denervation' (TLD), a novel bronchoscopic therapy based on ablation of parasympathetic pulmonary nerves surrounding the main bronchi, as a potential therapy for COPD.
methodsThis 1-year, prospective, multicentre study evaluated TLD in patients with COPD forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) (FEV1/FVC <0.70; FEV1 30%-60% predicted). Patients underwent staged TLD at 20 watts (W) or 15 W following baseline assessment off bronchodilators. Assessments were repeated on tiotropium before treatment and off bronchodilators at 30, 90, 180, 270 and 365 days after TLD. The primary endpoint was freedom from documented and sustained worsening of COPD directly attributable to TLD to 1 year. Secondary endpoints included technical feasibility, change in pulmonary function, exercise capacity, and quality of life.
resultsTwenty-two patients were included (n=12 at 20 W, n=10 at 15 W). The procedures were technically feasible 93% of the time. Primary safety endpoint was achieved in 95%. Asymptomatic bronchial wall effects were observed in 3 patients at 20 W. The clinical safety profiles were similar between the two energy doses. At 1 year, changes from baseline in the 20 W dose compared to the 15 W dose were: FEV1 (+11.6%±32.3 vs +0.02%±15.1, p=0.324), submaximal cycle endurance (+6.8 min±12.8 vs 2.6 min±8.7, p=0.277), and St George's Respiratory Questionnaire (-11.1 points ±9.1 vs -0.9 points ±8.6, p=0.044).
conclusionsBronchoscopic TLD, based on the concept of ablating parasympathetic pulmonary nerves, was feasible, safe, and well tolerated. Further investigation of this novel therapy is warranted. TRIAL REGISTRATION NUMBER: NCT01483534.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.